A recent study revealed a new oral weight to lose weight that can help burn fat and reduce blood sugar levels, just like the Osmbek and other Glucagon-Like Peptide-1 Agonists, but without causing muscle loss, and the new drug is currently undergoing human experiences.
The study was conducted by an international team of researchers led by “Atrogi AB” for biotechnology, and its results were published in the “Cell” magazine on June 23, and the American magazine Newsweek wrote about it.
“This medicine represents an entirely new type of treatments, and it is of great importance for type 2 diabetics and obesity,” said Professor Shin Wright, co -author of the study from the Carolinska Institute in Sweden.
Bulka-like bitchids-1, such as Olyzbek partly by changing brain and intestine signals to reduce hunger, may include side effects of muscle mass loss.
The new drug belongs to the Beta 2 Agonist family, which works by activating the paths of signals in the body in a way that positively affects the muscles, and the beta -2 receptors use the treatment of asthma and chronic obstructive pulmonary disease, and the new drug does not cause excessive stimulation of the heart unlike the exact receptors of the current beta -2 receptors.
The drug has proven its benefits in mice models with diabetes and patterns of obesity in both the formation of the body and control of blood sugar.
The results of a clinical trial from the first stage (which included 48 healthy people and 25 people with type 2 diabetes) showed that the drug is safe, while the effectiveness of the new treatment has not yet been established on humans.
“Our results indicate a future in which we can improve metabolic health without losing muscle mass,” said Tori Pingson, professor of molecular biology at the Swedish Stockholm University and co -author of the study.
He added: “The muscles are important in both type 2 diabetes and obesity, and the muscle mass is directly related to the average life expectancy.”
The team made it clear that one of the advantages of the new drug is that it can be taken with Ozmbek and other bitchids similar to the glucagon-1, due to the different mechanism of its work.
“This makes her valuable as an independent treatment or in combination with bitchy-like bituch-1 drugs,” Wright said.
After the completion of this initial study, researchers are now looking to conduct a broader study to see whether the drug provides the same benefits to humans with type 2 diabetes or obesity as was the case in mice models affected by these cases.